Macrocyclic MCL-1 inhibitors and methods of use
US-2019055264-A1 · Feb 21, 2019 · US
Macrocyclic MCL-1 inhibitors and methods of use
US10676485B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10676485-B2 |
| Application number | US-201815998789-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 15, 2018 |
| Priority date | Aug 15, 2017 |
| Publication date | Jun 9, 2020 |
| Grant date | Jun 9, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides for compounds of formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
First claim
Opening claim text (preview).
We claim: 1. A compound having the structure: or a pharmaceutically acceptable salt thereof. 2. A compound having the structure:
Assignees
Inventors
Classifications
ortho- or peri-condensed with heterocyclic rings · CPC title
Antineoplastic agents · CPC title
in which the condensed system contains four or more hetero rings · CPC title
specific for leukemia · CPC title
- C07D495/16Primary
Peri-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10676485B2 cover?
- The present disclosure provides for compounds of formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, includ…
- Who is the assignee on this patent?
- Abbvie Inc, Abbvie Deutschland
- What technology area does this patent fall under?
- Primary CPC classification C07D495/16. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).